By Editor , 31 October 2026
Atomera Q3 Net Loss Widens to $6.0M as GAA Customers Reach Three
Atomera Q3 Net Loss Widens to $6.0M as GAA Customers Reach Three

LOS GATOS – October 30, 2026 -- Atomera Incorporated (NASDAQ: ATOM) reported a third-quarter 2026 net loss of $6.0 million, or $0.15 per share, while cash and short-term investments rose to $34.8 million from $19.2 million at year-end 2025.

Net loss widens by $0.4 million while per-share loss narrows to $0.15

The loss compares with $5.6 million, or $0.17 per share, in the third quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was a loss of $4.6 million versus a loss of $4.4 million a year earlier. Shares outstanding totaled 39.1 million as of Sept. 30, 2026.

The cash balance as of Sept. 30 is $15.6 million higher than at Dec. 31, 2025.

Atomera raises gate-all-around engagements to three customers

The semiconductor materials and technology licensing company increased its engagement count in gate-all-around transistors to three customers. CEO Scott Bibaud said its nano-scale diffusion blocking work has drawn interest from GAA foundries and from designers of next-generation memory. He attributed demand for higher transistor performance to AI.

Atomera also demonstrated what it describes as a simpler, lower-cost approach to enable next-generation DRAM transistors using its Mears Silicon Technology (MST).

IQE joint development agreement targets RF GaN-on-silicon

Atomera signed a Joint Development Agreement with IQE, a compound semiconductor wafer supplier, to bring high-performance, cost-effective RF GaN to market. Bibaud called the deal an "important step" toward commercializing the company's GaN-on-silicon solutions.

Revenue remains minimal and licensing conversion is unproven

Atomera states that it has recognized only minimal engineering services and licensing revenues to date. It lists as a key risk that licensees or JDA customers may not advance to royalty-based manufacturing and distribution licenses. It also cites its ability to raise sufficient capital, as and when needed, as a risk to commercializing MST.

Target market(s)
Editorial Review Status
Human Passed (Editor Approved)